Last reviewed · How we verify

Autologous Bone Marrow Aspirate Concentrate

CELL Technologies Inc. · Phase 3 active Biologic

Autologous bone marrow aspirate concentrate delivers a patient's own bone marrow-derived cells (including mesenchymal stem cells and hematopoietic progenitors) to promote tissue repair and reduce inflammation.

Autologous bone marrow aspirate concentrate delivers a patient's own bone marrow-derived cells (including mesenchymal stem cells and hematopoietic progenitors) to promote tissue repair and reduce inflammation. Used for Orthopedic injuries and degenerative joint disease (Phase 3 development), Musculoskeletal tissue repair.

At a glance

Generic nameAutologous Bone Marrow Aspirate Concentrate
Also known asBMAC
SponsorCELL Technologies Inc.
Drug classCell therapy; autologous stem cell product
ModalityBiologic
Therapeutic areaRegenerative Medicine; Orthopedics; Musculoskeletal
PhasePhase 3

Mechanism of action

The product is prepared by aspirating bone marrow from the patient, concentrating the nucleated cell fraction, and reinjecting it into damaged tissue. The mechanism relies on the regenerative and immunomodulatory properties of bone marrow stem cells, which can differentiate into tissue-specific cells, secrete anti-inflammatory cytokines, and promote angiogenesis. This autologous approach avoids immune rejection and leverages the body's own repair mechanisms.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: